Sunnybrook Health Sciences Centre

The judicious use of stereotactic radiosurgery and hypofractionated stereotactic radiotherapy in the management of large brain metastases (2021) Gutschenritter T, Venur VA, Combs SE, Vellayappan B, Patel AP, Foote M, Redmond KJ, et al. Journal article, Review article Care for neuroendocrine tumor patients, monitored by medical oncologists: Comparative data Europe vs North America (2021) Kolarova T, Mcdonnell M, Bouvier CV, Pavel ME, Singh H, Howe J, Singh S, et al. Conference contribution Comparison of ped and fred flow diverters for posterior circulation aneurysms: a propensity score matched cohort study (2020) Griessenauer CJ, Enriquez-Marulanda A, Xiang S, Hong T, Zhang H, Taussky P, Grandhi R, et al. Journal article Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials (2019) Yao J, Garg A, Chen D, Capdevila J, Engstrom P, Pommier R, Van Cutsem E, et al. Journal article Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification (2019) Yoon SH, Whisenant BK, Bleiziffer S, Delgado V, Dhoble A, Schofer N, Eschenbach L, et al. Journal article Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes With Everolimus: A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials (2019) Chan DL, Yao JC, Camaghi C, Herbst F, Ridolfi A, Strosberg J, Kulke MH, et al. Conference contribution Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) (2018) Yao JC, Strosberg J, Fazio N, Pavel ME, Ruszniewski P, Bergsland E, Li D, et al. Conference contribution ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment (2018) Yao JC, Fazio N, Li D, Pavel ME, Strosberg J, Bergsland E, Ruszniewski P, et al. Conference contribution Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution Efficacy and safety of nilotinib in patients with kit-mutated metastatic or inoperable melanoma: Final results from the global, single-arm, phase ii team trial (2017) Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, et al. Journal article